Exagen Q2 EPS $(0.28) Beats $(0.48) Estimate, Sales $14.14M Beat $10.97M Estimate
Portfolio Pulse from Benzinga Newsdesk
Exagen (NASDAQ:XGN) reported Q2 earnings per share of $(0.28), beating the analyst consensus estimate of $(0.48) by 41.67%. The company also reported quarterly sales of $14.14 million, surpassing the analyst consensus estimate of $10.97 million by 28.90%. This represents a 64.1% increase in earnings and a 57.78% increase in sales compared to the same period last year.
August 07, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exagen's Q2 earnings and sales exceeded analyst estimates, indicating a strong financial performance.
Exagen's better-than-expected Q2 results indicate a strong financial performance, which is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100